Tokyo, July 30, 2008 (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai China Inc. (‘ECI’), a wholly-owned subsidiary of Eisai Co., Ltd., has entered into license agreement with Health Vision Enterprise Ltd., a sales subsidiary of STADA Arzneimittel AG, for sales and repack of Alpha-Lipon 300 STADA(R) (generic name: alpha-lipoic acid) in China. Alpha-Lipon 300 STADA is a treatment for diabetic neuropathic pain developed by STADA.
